BACKGROUND: During long-term multiple sclerosis therapy, patient satisfaction with received treatment has considerable impact on treatment outcomes. Here we report the results of a non-interventional real-world study that mapped the treatment patterns of disease-modifying therapy (DMT) and assessed treatment satisfaction with DMT. PATIENTS AND METHODS: The SKARLET study was a non-interventional, cross-sectional study in Slovakia running from May 2016 to March 2017. Patients with relapsing-remitting multiple sclerosis on DMT for ≥3 months and ≤2 years (per local labelling) from 10 multiple sclerosis centers across Slovakia were included. The primary objective was to collect the Treatment Satisfaction Questionnaire for Medication version 9 (TSQM 9) score regarding perceived effectiveness, convenience and overall satisfaction with DMT. RESULTS: The following TSQM 9 scores (mean; 95% confidence interval) were reported from 415 patients: convenience (75.05; 73.49-76.61), effectiveness (68.15; 66.56-69.75) and global satisfaction scale (66.94; 65.26-68.62). All three parameters of the TSQM 9 were analyzed by the route of DMT administration, with infusions best rated for effectiveness and global satisfaction in comparison to oral dosage and injections. For convenience, however, oral dosage forms were appraised highly (82.66; 80.59-84.73) followed by infusions (74.40; 70.12-78.69), while injections were rated as the worst (66.92; 64.81-69.04). The difference of TSQM 9 scores according to the route of DMT administration is statistically significant for convenience (p < 0.001) and global satisfaction (p = 0.004), but not for effectiveness (p = 0.185). CONCLUSION: In the present study, it was confirmed that patients find oral DMTs as most convenient; however, the infusion form of treatment outweighs oral DMTs in global satisfaction and effectiveness. The differences of TSQM 9 scores among DMT dosage forms were significant for convenience and global satisfaction. In conclusion, the results of this detailed survey increase our understanding of RRMS patient population characteristics and patient satisfaction with DMT treatment.

1st Department of Neurology Faculty of Medicine Comenius University Bratislava 81369 Slovak Republic

NEOX Clinical Research Prague 1 110 00 Czech Republic

Sanofi Aventis Slovakia Bratislava 851 01 Slovak Republic

Zobrazit více v PubMed

Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25:215–237. doi:10.1111/ene.13536 PubMed DOI

Mendel R, Traul-Mattausch E, Frey D, et al. Do physicians’ recommendations pull patients away from their preferred treatment options? Health Expect. 2012;15(1):23–31. doi:10.1111/j.1369-7625.2010.00658.x PubMed DOI PMC

Albrecht G, Hoogstraten J. Satisfaction as a determinant of compliance. Community Dent Oral Epidemiol. 1998;26:139–146. doi:10.1111/j.1600-0528.1998.tb01940.x PubMed DOI

Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013;11:167. doi:10.1186/1477-7525-11-167 PubMed DOI PMC

Turk-Adawi K, Oldridge N, Tarima S, Stason W, Shepard D. Cardiac rehabilitation patient and organizational factors: what keeps patients in programs? J Am Heart Assoc. 2013;2:e000418. doi:10.1161/JAHA.113.000418 PubMed DOI PMC

Chrystyn H, Small M, Milligan G, Higgins V, Gil E, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365. doi:10.1016/j.rmed.2013.09.021 PubMed DOI

Wong W, Chow Y, Chen P, Wong S, Fielding R. A longitudinal analysis on pain treatment satisfaction among Chinese patients with chronic pain: predictors and association with medical adherence, disability, and quality of life. Qual Life Res. 2015;24:2087–2097. doi:10.1007/s11136-015-0955-1 PubMed DOI

Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30:89–100. doi:10.2165/11533330-000000000-00000 PubMed DOI

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292‐302. doi:10.1002/ana.22366 PubMed DOI PMC

Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. doi:10.1186/1477-7525-7-36 PubMed DOI PMC

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale EDSS. Neurology. 1983;33(11):1444–1452. doi:10.1212/WNL.33.11.1444 PubMed DOI

International Conference on Harmonisation Expert Working Group. ICH harmonized tripartite guideline guideline for good clinical practice E6(R1); 2016. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. accessed November11, 2015.

World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects; 2016. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. accessed November11, 2015.

Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9:250–263. doi:10.1177/1756285616634247 PubMed DOI PMC

Hanson K, Agashivala N, Stringer S, Balantac Z, Brandes D. A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod. Patient Prefer Adherence. 2013;309. doi:10.2147/PPA.S41992 PubMed DOI PMC

Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Treatment Satisfaction in Multiple Sclerosis. Int J MS Care. 2014;16:68–75. doi:10.7224/1537-2073.2013-021 PubMed DOI PMC

Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107–115. doi:10.1016/j.msard.2017.07.006 PubMed DOI

Eagle T, Stuart F, Chua AS, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196–201. doi:10.1016/j.msard.2017.10.002 PubMed DOI

Fernández O, Duran E, Ayuso T, Hernández L, Bonaventura I, Forner M, on behalf of the STICK Study Investigators Group. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study). PLoS One. 2017;12:e0185766. doi:10.1371/journal.pone.0185766. PubMed DOI PMC

Mékiès C, Heinzlef O, Jenny B, Ramelli A-L, Clavelou P. Treatment satisfaction and quality of life in patients treated with fingolimod. Patient Prefer Adherence. 2018;12:899–907. doi:10.2147/PPA.S144021 PubMed DOI PMC

Brola W, Sobolewski P, Fudala M, et al. Self-reported quality of life in multiple sclerosis patients: preliminary results based on the Polish MS Registry. Patient Prefer Adherence. 2016;10:1647–1656. doi:10.2147/PPA.S109520 PubMed DOI PMC

Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–1357. doi:10.2147/NDT.S132079 PubMed DOI PMC

Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK. Measuring treatment satisfaction in MS: is the treatment satisfaction questionnaire for medication fit for purpose? Mult Scler J. 2017;23:604–613. doi:10.1177/1352458516657441 PubMed DOI PMC

Calkwood J, Cree B, Crayton H, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014;14. doi:10.1186/s12883-014-0220-1. PubMed DOI PMC